All the Active Ingredient Drugs
Pazopanib 200 mg, 400 mg. Caps 200/400 mg X 30/60/90
800 mg once/d
Renal cell carcinoma (RCC): in adults for the first line tmt. of adv. RCC and for pts who have received prior cytokine ther. for adv. dis.
Soft tissue sarcoma (STS): for adult pts. with selective subtypes of adv. STS who have received prior chemother. for metast. dis. or who have progressed within 12 mo. after (neo) adjuvant ther.
C/I: Hypersens.
Protein Kinase Inhibitor. Pazopanib (HCl) 200 mg, 400 mg. F.C. TABS: 30 x 200 mg; 30 x 400 mg.
Adult.: Tmt. of RCC or STS is 800 mg
once dly.
Dose modific. should be in 200 mg
increm. in a stepwise fashion based
on individ. tolerab. in order to
manage ADR’s. Should not exceed
800 mg/d. See lit.
Ren. cell carcinoma (RCC): First line tmt.
of advanced RCC, and pts. receiv. prior
cytokine ther. advanced dis. Soft tissue
sarcoma (STS): Tmt. adult pts. with select.
subtypes advanced STS who have receiv.
prior chemother. for metastat. dis/
progress. within 12 months aft. (neo)
adjuv. ther.
C/I: Hypersens.
